30-Oct-2026 13:33:18
VIMTA LABS Q2 FY27: REVENUE UP 10% YOY; EBITDA UP 10.5%, ₹27.2 CR H1 CAPEX & CAPACITY EXPANSION PLANS
• Quarterly Results: Revenue from operations increased 10% YoY to ₹112 Cr, EBITDA grew 10.5% to ₹40.8 Cr and PAT increased 3.5% to ₹20.6 Cr • Margin Performance: EBITDA margin stood at 35.5% versus 35.3% YoY and 36.4% QoQ, while PAT margin declined to 17.9% from 19.1% YoY • H1 Performance: Total income increased 11.8% YoY to ₹227.8 Cr, EBITDA grew 13.2% to ₹81.9 Cr and PAT increased 7.3% to ₹41.7 Cr • Capex Investment: H1 FY27 total capex stood at ₹27.2 Cr, while Q2 capex cash outflow was ₹9.2 Cr, supporting ongoing infrastructure and technology investments • Capacity Expansion: Management plans further expansion of laboratory capacities to support growing demand across pharmaceutical research, food testing and electronics testing • Pharma Business: Focused on expanding drug discovery, analytical testing, preclinical research and clinical research services to capture opportunities in complex generics and biologics • Biologics Expansion: Strengthening contract research and development capabilities across cell-line development, process development, formulation and analytical services • Electronics Testing: Targeting opportunities in defence, aerospace, electric vehicles, medical devices, telecom and consumer electronics certification • Food & Environmental Testing: Plans to capitalise on increasing food safety regulations, environmental compliance requirements and demand for independent testing services • International Business: Overseas markets contribute approximately 40% of Pharma Analytical revenue and 75% of Clinical Research revenue • Market Position: Company ranks among India's top three preclinical service providers and top two food and environmental testing companies, according to its presentation • Cash Position: Cash and bank balances stood at ₹70.1 Cr against total debt of ₹14.4 Cr as of September 2026 • Future Growth Plans: Focused on new market penetration, service innovation, customer partnerships, advanced technologies, operational efficiency and expanding testing capabilities • FY27 Guidance: No specific FY27 revenue growth, EBITDA margin or future quantified capex guidance
VIMTA LABS LIMITED